PMV Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMVP research report →
Range $5 – $5
Price Chart
About the company
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state.
- CEO
- David H. Mack
- IPO
- 2020
- Employees
- 54
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on PMVP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $85.86M
- P/E
- -1.13
- PEG
- -0.12
- P/S
- 0.00
- P/B
- 1.20
- EV/EBITDA
- -0.97
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -78.11%
- ROIC
- -111.08%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-86,206,000
- Net Income
- $-77,742,000-32.4%
- EPS
- $-1.48-30.0%
- OCF Growth
- -43.5%
- FCF Growth
- -41.7%
- 52W High
- $1.91
- 52W Low
- $1.02
- 50D MA
- $1.33
- 200D MA
- $1.29
- Beta
- 1.35
- RSI (14)
- 58
- Avg Volume
- 652.89K
No earnings-call transcripts are available for PMVP yet.
- Free Float
- 91.7%
- Shares Outstanding
- 53.33M
- Float Shares
- 48.90M
of shares held by institutions
70 13F filers
Buy/sell ratio 6.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bml Capital Management, LLC | 5.33M | ▲ 10.00K |
| Tang Capital Management LLC | 4.25M | 0 |
| Sio Capital Management, LLC | 2.63M | ▼ 442.44K |
| Euclidean Capital LLC | 2.63M | 0 |
| Adage Capital Partners Gp, L.L.C. | 2.36M | ▲ 500.00K |
| Acadian Asset Management LLC | 2.22M | 0 |
| Vanguard Group Inc | 2.17M | ▲ 7.28K |
| Vanguard Capital Management LLC | 2.01M | ▲ 37.11K |
| Arrowmark Colorado Holdings LLC | 1.96M | ▼ 913.18K |
| Two Sigma Investments, LP | 1.95M | ▲ 69.61K |
| Eversept Partners, LP | 1.89M | ▼ 457.46K |
| Blackrock, Inc. | 919.82K | ▲ 45.44K |
Held by 30 ETFs
Biggest fund positions in PMVP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Eckler Matthew Joseph | other | 84,000 |
| Oct 1, 26 | Eckler Matthew Joseph | other | 0 |
| Jun 4, 26 | Stelzer Laurie | other | 42,000 |
| Jun 4, 26 | LEVINE ARNOLD J | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | Gallagher Carol Giltner | other | 42,000 |
| Jun 4, 26 | FLOWERS KIRSTEN | other | 42,000 |
| Jun 4, 26 | BAUM CHARLES M | other | 42,000 |
| Mar 5, 26 | Carulli Michael | other | 240,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PMVP coverage
Recent articles, reports, and earnings notes.
No research on PMVP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMVP report →PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts
defenseworld.net · Sep 29
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
zacks.com · Sep 16
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
globenewswire.com · Aug 31
PMV Pharma Announces Proposed Public Offering of Securities
globenewswire.com · Aug 31
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
globenewswire.com · Aug 31
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Aug 19
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Aug 14
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
zacks.com · Jun 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.